CTOs on the Move


 
At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.vyriad.com
  • 2900 37th Street NW Building 110
    Rochester, MN USA 55901
  • Phone: 507.289.0944

Executives

Name Title Contact Details

Funding

Vyriad raised $24.3M on 11/22/2019

Similar Companies

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.

Lifesprout

Revolutionary Products for Soft Tissue Replacement and Regeneration

Shionogi USA

Shionogi USA, Inc. is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syantra

With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.

Omnicare Distribution Center

Omnicare Distribution Center is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.